Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH -- Ignore unavailable to you. Want to Upgrade?

To: TokyoMex who wrote (722)	5/12/1998 7:28:00 PM
From: tranzz	Read Replies (1) \| Respond to of 998

Here is the news: ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ MORE) DOW JONES NEWS 05-12-98 06:23 PM FDA Cephalon -2-: Steps Needed For Lou Gehrig's Disease Drug WASHINGTON (Dow Jones)--The U.S. Food and Drug Administration issued an approvable letter to Cephalon Inc. (CEPH) and Chiron Corp. (CHIR) Tuesday for their drug Myotrophin, designed to treat Lou Gehrig's disease. An approvable letter outlines what steps the FDA wants a company to take before it will clear a drug for marketing. Myotrophin will be Cephalon's first drug on the market, but it wasn't a shoo-in. FDA expert panels weren't convinced the drug was effective in prolonging lives of patients with the incurable central nervous system disorder, officially called amyotrophic lateral sclerosis. The disease attacks nerves in the brain and spinal cord, which leads to paralysis and death. A clinical trial of the drug, conducted in the U.S., showed it prolonged some patients' lives up to three months. However, another study, in Europe, didn't show any benefit to patients using the drug. The conflicting studies led an FDA advisory panel to recommend against approving the drug in May 1997. In 1996, the same panel urged the companies to conduct a tie-breaking study, but the companies instead resubmitted the same two studies with a different analysis of the data. Another panel review, scheduled for last month, was canceled after the FDA said it needed more time to study the drug and its data. Lou Gehrig's disease, named for the famous baseball player who died from it, affects about 30,000 Americans. -Otesa Middleton; 202-862-6654 (END) DOW JONES NEWS 05-12-98 06:52 PM Copyright c 1998 Dow Jones & Company, Inc.